Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) EBIT Margin (2021 - 2025)

Historic EBIT Margin for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to 102.64%.

  • Rhythm Pharmaceuticals' EBIT Margin rose 293400.0% to 102.64% in Q3 2025 from the same period last year, while for Sep 2025 it was 106.81%, marking a year-over-year increase of 1291400.0%. This contributed to the annual value of 204.04% for FY2024, which is 340700.0% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its EBIT Margin stood at 102.64% for Q3 2025, which was up 293400.0% from 93.39% recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' EBIT Margin peaked at 93.39% during Q2 2025, and registered a low of 98280.0% during Q1 2021.
  • In the last 5 years, Rhythm Pharmaceuticals' EBIT Margin had a median value of 458.03% in 2023 and averaged 6730.04%.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' EBIT Margin soared by 947625800bps in 2022, and later crashed by -806800bps in 2024.
  • Rhythm Pharmaceuticals' EBIT Margin (Quarter) stood at 2806.22% in 2021, then skyrocketed by 83bps to 478.99% in 2022, then skyrocketed by 64bps to 170.28% in 2023, then skyrocketed by 42bps to 98.63% in 2024, then dropped by -4bps to 102.64% in 2025.
  • Its EBIT Margin was 102.64% in Q3 2025, compared to 93.39% in Q2 2025 and 143.73% in Q1 2025.